TORONTO and HAIFA, Israel, Aug. 14, 2026 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (“NurExone” or the “Company“) (TSXV: NRX, OTCQB: NRXBF, FSE: J90), a biotechnology company developing exosome-based regenerative therapies, today announced new preclinical tissue-analysis results that provide additional biological support for ExoPTEN’s potential neuroprotective effect in an animal model of traumatic spinal cord injury.
The findings provide an important new biological dimension to the ExoPTEN’s efficacy profile.
NurExone has previously reported improved functional recovery in animals treated with ExoPTEN (press release dated July 8, 2025). In the current analysis, spinal cord tissue collected from those same animals and evaluated to assess biological markers associated with neurons and supporting structures. Two months after injury, ExoPTEN-treated animals showed significantly higher numbers of cells positive for Myelin Basic Protein (“MBP”), a key component of the protective coating surrounding nerve fibers, compared with controls in regions on both sides of the injury site.
These data further inform NurExone’s understanding of ExoPTEN’s potential mechanism of action and contribute to the scientific and regulatory foundation supporting the program as it advances through preclinical development toward potential clinical development.